InflaRx N.V., a clinical-stage biopharmaceutical company, placed 6,667,000 common shares in the IPO with a share price of $15.00 raising approximately $100 million of primary gross proceeds (total market capitalisation of $351,164,580). Trading of the shares on the NASDAQ Global Select Market commenced on 8 November 2017 under the ticker symbol “IFRX”.

Loyens & Loeff acted as Dutch corporate counsel to the underwriters. In this transaction Loyens & Loeff worked closely together with Goodwin Procter LLP.